158 related articles for article (PubMed ID: 37023798)
1. Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets.
Katta SS; Nagati V; Paturi ASV; Murakonda SP; Murakonda AB; Pandey MK; Gupta SC; Pasupulati AK; Challagundla KB
J Control Release; 2023 May; 357():444-459. PubMed ID: 37023798
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the developmental origin of neuroblastoma: an overview.
Ponzoni M; Bachetti T; Corrias MV; Brignole C; Pastorino F; Calarco E; Bensa V; Giusto E; Ceccherini I; Perri P
J Exp Clin Cancer Res; 2022 Mar; 41(1):92. PubMed ID: 35277192
[TBL] [Abstract][Full Text] [Related]
4. The quest to develop an effective therapy for neuroblastoma.
Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
[TBL] [Abstract][Full Text] [Related]
5. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
6. Cell death-based treatment of neuroblastoma.
Valter K; Zhivotovsky B; Gogvadze V
Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
Czarnecka M; Trinh E; Lu C; Kuan-Celarier A; Galli S; Hong SH; Tilan JU; Talisman N; Izycka-Swieszewska E; Tsuei J; Yang C; Martin S; Horton M; Christian D; Everhart L; Maheswaran I; Kitlinska J
Oncogene; 2015 Jun; 34(24):3131-43. PubMed ID: 25132261
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
Sabbih GO; Danquah MK
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
[TBL] [Abstract][Full Text] [Related]
9. An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma.
Baldini F; Calderoni M; Vergani L; Modesto P; Florio T; Pagano A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921816
[TBL] [Abstract][Full Text] [Related]
10. Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity.
D'Amico S; Tempora P; Gragera P; Król K; Melaiu O; De Ioris MA; Locatelli F; Fruci D
Front Immunol; 2023; 14():1268645. PubMed ID: 37849756
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development.
Tomolonis JA; Agarwal S; Shohet JM
Cell Tissue Res; 2018 May; 372(2):245-262. PubMed ID: 29222693
[TBL] [Abstract][Full Text] [Related]
12. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
13. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
14. State of the art in immunotherapy of neuroblastoma.
Jabbari P; Hanaei S; Rezaei N
Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
[TBL] [Abstract][Full Text] [Related]
15. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
16. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.
Wang Y; Chen K; Cai Y; Cai Y; Yuan X; Wang L; Wu Z; Wu Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):111. PubMed ID: 28814318
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution.
Aravindan N; Subramanian K; Somasundaram DB; Herman TS; Aravindan S
Cancer Drug Resist; 2019; 2(4):1086-1105. PubMed ID: 31867575
[TBL] [Abstract][Full Text] [Related]
18. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract][Full Text] [Related]
19. Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target.
Yco LP; Geerts D; Mocz G; Koster J; Bachmann AS
BMC Cancer; 2015 Jun; 15():477. PubMed ID: 26093909
[TBL] [Abstract][Full Text] [Related]
20. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
